Renflexis (infliximab) is a biologic medicine that helps the pain and swelling of arthritis. Renflexis belongs to a class of similar medications called Anti-Tumor Necrosis Factor agents.
The medication works by blocking Tumor Necrosis Factor (TNF), a type of signalling protein called a cytokine that is involved in systemic inflammation.
Renflexis is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that has been designed to be identical to an existing biologic medication, but is created using a different process.
Renflexis is a biosimilar of Remicade. Both medications are known by the same generic name: infliximab. Biosimilars are often cheaper than the original medication.
Renflexis is administered by intravenous infusion at specialized clinics.
Some patients start to feel better quickly with Renflexis, but in others, it can take a little longer.
It's important for patients starting this medication to give it some time and keep receiving infusions as prescribed by their doctor.
The manufacturer of Renflexis offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Watch Canadian rheumatologist Dr. Andy Thompson introduce Renflexis in this short video:
Drug Identification Number (DIN)